Z
36.31
-0.27 (-0.74%)
| Previous Close | 36.58 |
| Open | 36.37 |
| Volume | 381,112 |
| Avg. Volume (3M) | 440,549 |
| Market Cap | 1,949,090,688 |
| Price / Earnings (TTM) | 2.66 |
| Price / Sales | 102.28 |
| Price / Book | 10.00 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -373.30% |
| Diluted EPS (TTM) | -3.89 |
| Total Debt/Equity (MRQ) | 0.43% |
| Current Ratio (MRQ) | 6.47 |
| Operating Cash Flow (TTM) | -137.62 M |
| Levered Free Cash Flow (TTM) | -77.73 M |
| Return on Assets (TTM) | -56.70% |
| Return on Equity (TTM) | -115.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Zenas BioPharma, Inc. | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 21.20% |
| % Held by Institutions | 74.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Enavate Sciences Gp, Llc | 30 Sep 2025 | 3,761,359 |
| Pivotal Bioventure Partners Investment Advisor Llc | 30 Sep 2025 | 779,045 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (Evercore ISI Group, 51.47%) | Buy |
| Median | 45.00 (23.93%) | |
| Low | 37.00 (Morgan Stanley, 1.90%) | Buy |
| Average | 45.40 (25.03%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 35.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 22 Dec 2025 | 45.00 (23.93%) | Buy | 42.33 |
| 09 Oct 2025 | 40.00 (10.16%) | Buy | 27.76 | |
| Evercore ISI Group | 26 Nov 2025 | 55.00 (51.47%) | Buy | 40.53 |
| Morgan Stanley | 13 Nov 2025 | 37.00 (1.90%) | Buy | 35.66 |
| 28 Oct 2025 | 34.00 (-6.36%) | Buy | 30.19 | |
| Citigroup | 28 Oct 2025 | 46.00 (26.69%) | Buy | 30.19 |
| HC Wainwright & Co. | 28 Oct 2025 | 44.00 (21.18%) | Buy | 30.19 |
| 09 Oct 2025 | 30.00 (-17.38%) | Buy | 27.76 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |